First artemisinin-based antimalarial combination approved for U.S. market.
Cheryl A
CA
Thompson
D000284:Administration, Oral; D000962:Antimalarials / Q000009:adverse effects / Q000627:therapeutic use*; D000077549:Artemether; D037621:Artemisinins / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D005449:Fluorenes / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000078102:Lumefantrine; D008288:Malaria / Q000188:drug therapy* / Q000517:prevention & control; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration
D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D013607:Tablets; D000077549:Artemether; D000078102:Lumefantrine